Breast cancer: new aspects of adjuvant hormonal therapy

被引：2
作者：
Lohrisch, C [1 ]
Piccart, M
机构：
[1] EORTC, Invest Drug Branch Breast Canc, Brussels, Belgium
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
10.1023/A:1011190923930
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：13 / 25
页数：13
相关论文
共 63 条
[1]  
[Anonymous], P AM SOC CLIN ONCOL
[2]  
[Anonymous], P ASCO
[3]   EXPRESSION OF RAS P21, P53 AND C-ERBB-2 IN ADVANCED BREAST-CANCER AND RESPONSE TO FIRST LINE HORMONAL-THERAPY [J].
ARCHER, SG ;
ELIOPOULOS, A ;
SPANDIDOS, D ;
BARNES, D ;
ELLIS, IO ;
BLAMEY, RW ;
NICHOLSON, RI ;
ROBERTSON, JFR .
BRITISH JOURNAL OF CANCER, 1995, 72 (05) :1259-1266
[4]  
AWADA A, 1997, CONSULTANT SERIES, V18, P71
[5]   Fadrozole versus megestrol acetate: A double-blind randomised trial in advanced breast cancer [J].
Bezwoda, WR ;
Gudgeon, A ;
Falkson, G ;
Jordaan, JP ;
Goedhals, L .
ONCOLOGY, 1998, 55 (05) :416-420
[6]  
BIANCO AR, 1998, P AN M AM SOC CLIN, V17, P97
[7]  
BIANCO AR, 2000, P AN M AM SOC CLIN, V19, pA75
[8]   ERBB2 AMPLIFICATION IS ASSOCIATED WITH TAMOXIFEN RESISTANCE IN STEROID-RECEPTOR POSITIVE BREAST-CANCER [J].
BORG, A ;
BALDETORP, B ;
FERNO, M ;
KILLANDER, D ;
OLSSON, H ;
RYDEN, S ;
SIGURDSSON, H .
CANCER LETTERS, 1994, 81 (02) :137-144
[9]  
Buzdar AU, 1996, CANCER, V77, P2503, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO
[10]  
2-W
1234567